Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the consultation and would like to emphasise the following: 1. Ensure access: • HTA: RCE encourages the harmonisation of HTA processes and to ensure the concept of joint clinical assessments, to avoid the duplication of clinical assessments at national level, as foreseen by the draft HTA regulation.
RCE
Rare Cancers Europe
Other · Switzerland
not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts (staff, costs, accreditations) are not available for it.
3
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,800 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Track Rare in PolicySpeak: request access →
Work at Rare Cancers Europe? so we know who speaks for it.
Their record over time
Rare Cancers Europe filed 3 positions between 6 Jan 2021 and 27 Apr 2021, across 3 of the 665 legislative files tracked here, attaching a full position paper 3 times.
What they argued
Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the EU efforts towards the creation of a European Health Data Space (EHDS). Rare cancers are a neglected area deserving dedicated attention as 24% of all new cancer diagnoses, including all paediatric cancers, are rare.
Rare Cancers Europe (RCE), a 39 partner strong multi-stakeholder partnership, welcomes the EU efforts to assessing solutions to improve the legislative environment on medicines for rare diseases, including rare cancers. With more than 20% of all new cancer cases being rare, including all paediatric cancers, rare cancers belong to both cancers and rare diseases.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Rare Cancers Europe next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 86.
Is this your organization?
Everything on this page comes from Rare Cancers Europe’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.